592 related articles for article (PubMed ID: 12091877)
1. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1.
Luttun A; Tjwa M; Moons L; Wu Y; Angelillo-Scherrer A; Liao F; Nagy JA; Hooper A; Priller J; De Klerck B; Compernolle V; Daci E; Bohlen P; Dewerchin M; Herbert JM; Fava R; Matthys P; Carmeliet G; Collen D; Dvorak HF; Hicklin DJ; Carmeliet P
Nat Med; 2002 Aug; 8(8):831-40. PubMed ID: 12091877
[TBL] [Abstract][Full Text] [Related]
2. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1.
Autiero M; Waltenberger J; Communi D; Kranz A; Moons L; Lambrechts D; Kroll J; Plaisance S; De Mol M; Bono F; Kliche S; Fellbrich G; Ballmer-Hofer K; Maglione D; Mayr-Beyrle U; Dewerchin M; Dombrowski S; Stanimirovic D; Van Hummelen P; Dehio C; Hicklin DJ; Persico G; Herbert JM; Communi D; Shibuya M; Collen D; Conway EM; Carmeliet P
Nat Med; 2003 Jul; 9(7):936-43. PubMed ID: 12796773
[TBL] [Abstract][Full Text] [Related]
3. Placental growth factor (PlGF) and its receptor Flt-1 (VEGFR-1): novel therapeutic targets for angiogenic disorders.
Luttun A; Tjwa M; Carmeliet P
Ann N Y Acad Sci; 2002 Dec; 979():80-93. PubMed ID: 12543719
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization.
Viglietto G; Romano A; Manzo G; Chiappetta G; Paoletti I; Califano D; Galati MG; Mauriello V; Bruni P; Lago CT; Fusco A; Persico MG
Oncogene; 1997 Nov; 15(22):2687-98. PubMed ID: 9400995
[TBL] [Abstract][Full Text] [Related]
5. Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.
Lu D; Jimenez X; Zhang H; Wu Y; Bohlen P; Witte L; Zhu Z
Cancer Res; 2001 Oct; 61(19):7002-8. PubMed ID: 11585724
[TBL] [Abstract][Full Text] [Related]
6. Placenta growth factor stimulates MAP kinase and mitogenicity but not phospholipase C-gamma and migration of endothelial cells expressing Flt 1.
Landgren E; Schiller P; Cao Y; Claesson-Welsh L
Oncogene; 1998 Jan; 16(3):359-67. PubMed ID: 9467961
[TBL] [Abstract][Full Text] [Related]
7. Heterodimers of placenta growth factor/vascular endothelial growth factor. Endothelial activity, tumor cell expression, and high affinity binding to Flk-1/KDR.
Cao Y; Chen H; Zhou L; Chiang MK; Anand-Apte B; Weatherbee JA; Wang Y; Fang F; Flanagan JG; Tsang ML
J Biol Chem; 1996 Feb; 271(6):3154-62. PubMed ID: 8621715
[TBL] [Abstract][Full Text] [Related]
8. Tumor-specific regulation of angiogenic growth factors and their receptors during recovery from cytotoxic therapy.
Taylor AP; Osorio L; Craig R; Raleigh JA; Ying Z; Goldenberg DM; Blumenthal RD
Clin Cancer Res; 2002 Apr; 8(4):1213-22. PubMed ID: 11948135
[TBL] [Abstract][Full Text] [Related]
9. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
[TBL] [Abstract][Full Text] [Related]
10. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions.
Carmeliet P; Moons L; Luttun A; Vincenti V; Compernolle V; De Mol M; Wu Y; Bono F; Devy L; Beck H; Scholz D; Acker T; DiPalma T; Dewerchin M; Noel A; Stalmans I; Barra A; Blacher S; VandenDriessche T; Ponten A; Eriksson U; Plate KH; Foidart JM; Schaper W; Charnock-Jones DS; Hicklin DJ; Herbert JM; Collen D; Persico MG
Nat Med; 2001 May; 7(5):575-83. PubMed ID: 11329059
[TBL] [Abstract][Full Text] [Related]
11. Upregulation of vascular endothelial growth factor (VEGF) and downregulation of placenta growth factor (PlGF) associated with malignancy in human thyroid tumors and cell lines.
Viglietto G; Maglione D; Rambaldi M; Cerutti J; Romano A; Trapasso F; Fedele M; Ippolito P; Chiappetta G; Botti G
Oncogene; 1995 Oct; 11(8):1569-79. PubMed ID: 7478581
[TBL] [Abstract][Full Text] [Related]
12. VEGF receptor 1 stimulates stem-cell recruitment and new hope for angiogenesis therapies.
Eriksson U; Alitalo K
Nat Med; 2002 Aug; 8(8):775-7. PubMed ID: 12152025
[No Abstract] [Full Text] [Related]
13. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis.
Warren RS; Yuan H; Matli MR; Gillett NA; Ferrara N
J Clin Invest; 1995 Apr; 95(4):1789-97. PubMed ID: 7535799
[TBL] [Abstract][Full Text] [Related]
14. Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen--a review.
Ahmed A; Dunk C; Ahmad S; Khaliq A
Placenta; 2000; 21 Suppl A():S16-24. PubMed ID: 10831117
[TBL] [Abstract][Full Text] [Related]
15. Cell type-specific expression of neuropilins in an MCA-occlusion model in mice suggests a potential role in post-ischemic brain remodeling.
Beck H; Acker T; Püschel AW; Fujisawa H; Carmeliet P; Plate KH
J Neuropathol Exp Neurol; 2002 Apr; 61(4):339-50. PubMed ID: 11939589
[TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide.
Bussolati B; Dunk C; Grohman M; Kontos CD; Mason J; Ahmed A
Am J Pathol; 2001 Sep; 159(3):993-1008. PubMed ID: 11549592
[TBL] [Abstract][Full Text] [Related]
17. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel.
Inoue K; Slaton JW; Davis DW; Hicklin DJ; McConkey DJ; Karashima T; Radinsky R; Dinney CP
Clin Cancer Res; 2000 Jul; 6(7):2635-43. PubMed ID: 10914704
[TBL] [Abstract][Full Text] [Related]
18. Placenta growth factor-1 antagonizes VEGF-induced angiogenesis and tumor growth by the formation of functionally inactive PlGF-1/VEGF heterodimers.
Eriksson A; Cao R; Pawliuk R; Berg SM; Tsang M; Zhou D; Fleet C; Tritsaris K; Dissing S; Leboulch P; Cao Y
Cancer Cell; 2002 Feb; 1(1):99-108. PubMed ID: 12086892
[TBL] [Abstract][Full Text] [Related]
19. Angiogenesis therapy: amidst the hype, the neglected potential for serious side effects.
Epstein SE; Kornowski R; Fuchs S; Dvorak HF
Circulation; 2001 Jul; 104(1):115-9. PubMed ID: 11435348
[No Abstract] [Full Text] [Related]
20. Endothelial nitric oxide synthase is strongly expressed in malignant mesothelioma but does not associate with vascular density or the expression of VEGF, FLK1 or FLT1.
Soini Y; Puhakka A; Kahlos K; Säily M; Pääkkö P; Koistinen P; Kinnula V
Histopathology; 2001 Aug; 39(2):179-86. PubMed ID: 11493335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
